• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W.L. GORE & ASSOCIATES AORTIC TAG THORACIC ENDOPROSTHESIS (CTAG); SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W.L. GORE & ASSOCIATES AORTIC TAG THORACIC ENDOPROSTHESIS (CTAG); SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT Back to Search Results
Catalog Number TGU313115
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Code Aneurysm (1708)
Date of Event 02/01/2019
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
Patient medications include but are not limited to: trazodone, symbicort, travatan, lisinopril.According to the instructions for use (ifu) for the gore® tag® thoracic endoprosthesis; adverse events that may occur include, but are not limited to include: endoleak.A review of the manufacturing records for the device(s) verified that the lot(s) met all pre-release specifications.
 
Event or Problem Description
On (b)(6) 2016, this patient underwent endovascular treatment for a thoracic aortic arch aneurysm and was implanted with a conformable gore® tag® thoracic endoprosthesis.It was reported that placement was just distal to the innominate artery with coverage of the left subclavian artery (lsa).The lsa was reported to have been bypassed but not transposed.The patient tolerated the procedure.On (b)(6) 2019, the patient underwent reintervention for treatment of a type ii endoleak originating from the lsa.An additional conformable gore® tag® thoracic endoprosthesis was placed to reline the original graft and reinforce the radial force.The patient tolerated the procedure.Conclusion angiography was unable to determine if the endoleak was resolved.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
AORTIC TAG THORACIC ENDOPROSTHESIS (CTAG)
Common Device Name
SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT
Manufacturer (Section D)
W.L. GORE & ASSOCIATES
flagstaff AZ
MDR Report Key8338830
Report Number2017233-2019-00061
Device Sequence Number2138162
Product Code MIH
UDI-Device Identifier00733132617814
UDI-Public00733132617814
Combination Product (Y/N)N
Initial Reporter StateAL
Initial Reporter CountryUS
PMA/510(K) Number
P040043
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2016
Reporter Type Manufacturer
Report Source company representative
Initial Reporter Occupation Physician
Type of Report Initial
Report Date (Section B) 02/01/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Expiration Date10/31/2016
Device Catalogue NumberTGU313115
Device Lot Number12033781
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer Not provided
Initial Report FDA Received Date02/14/2019
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Patient Sequence Number1
Outcome Attributed to Adverse Event Hospitalization; Other; Required Intervention;
Patient Age60 YR
Patient Weight50
-
-